July 30, 2018
Global pharmaceutical leader selects innovative single-B-cell technology to generate breakthrough therapies CAMBRIDGE, Mass., SHANGHAI, China, and PARIS, France – July 30, 2018 – HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-B-cell screening and analysis, today announced a multi-target agreement with Takeda Pharmaceutical Company Limited (Takeda) to enable the discovery of...
Read More